Patients with atrial fibrillation enrolled in the ROCKET-AF trial--looking at whether the novel anticoagulant rivaroxaban is better than warfarin for preventing stroke--are at higher risk of stroke than those who have participated in other recent trials of novel agents for this indication. Heartwire